J. Eron

发表

Pharmacodynamics of Antiretroviral Agents in HIV-1 Infected Patients: Using Viral Dynamic Models that Incorporate Drug Susceptibility and Adherence

Alan S. Perelson, Hulin Wu, Song Yu, 2006, Journal of Pharmacokinetics and Pharmacodynamics.

Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy

Alyssa J. Porter, M. Zody, M. Lederman, 2014, PloS one.

Brief but efficient: acute HIV infection and the sexual transmission of HIV.

Christopher D Pilcher, Pietro L Vernazza, Li-Ean Goh, 2004, The Journal of infectious diseases.

Self‐report of current and prior antiretroviral drug use in comparison to the medical record among HIV‐infected patients receiving primary HIV care

J. Eron, S. Napravnik, E. Brouwer, 2011, Pharmacoepidemiology and drug safety.

Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.

D. Richman, H. Günthard, S. Frost, 2001, The Journal of infectious diseases.

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

E A Emini, D. Richman, D. Havlir, 1997, The New England journal of medicine.

Estimating multiple time‐fixed treatment effects using a semi‐Bayes semiparametric marginal structural Cox proportional hazards regression model

Catherine R. Lesko, S. Cole, S. Greenland, 2018, Biometrical journal. Biometrische Zeitschrift.

Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula

Richard D Moore, S. Cole, J. Eron, 2018, American journal of epidemiology.

LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

E. Daar, Davey M. Smith, C. Fletcher, 2021, Open Forum Infectious Diseases.

Unexpected Finding of Delayed-Onset Seizures in HIV-Positive, Treatment-Experienced Subjects in the Phase Iib Evaluation of Fosdevirine (Gsk2248761)

J. Eron, E. Dejesus, D. Margolis, 2014, Antiviral therapy.

Polyclonal B Cell Differentiation and Loss of Gastrointestinal Tract Germinal Centers in the Earliest Stages of HIV-1 Infection

Jörn E. Schmitz, Joseph J. Eron, Barton F. Haynes, 2009, PLoS medicine.

Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study

Richard D Moore, P. Volberding, S. Heckbert, 2020, BMJ Open.

Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study

P. Volberding, J. A. Delaney, S. Heckbert, 2020, BMC Infectious Diseases.

Class of antiretroviral drugs and anemia risk in the current treatment era

P. Volberding, S. Heckbert, M. Saag, 2019, bioRxiv.

Brief Report: Reduced Use of Illicit Substances, Even Without Abstinence, Is Associated With Improved Depressive Symptoms Among People Living With HIV

Richard D Moore, M. Saag, F. Altice, 2018, Journal of acquired immune deficiency syndromes.

Spatial Epidemiology of Recently Acquired HIV Infections across Rural and Urban Areas of North Carolina

M. Carrel, M. Emch, J. Eron, 2014, PloS one.

High clade C HIV-1 viremia: how did we get here and where are we going?

A. McMichael, Myron S. Cohen, K. Soderberg, 2011, AIDS.

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

J. Montaner, D. Kuritzkes, S. Walmsley, 2003, The New England journal of medicine.

Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.

J. Nachega, Ravindra K. Gupta, G. V. Van Zyl, 2013, The Journal of infectious diseases.

Association between First-Year Virological Response to Raltegravir and Long-Term Outcomes in Treatment-Experienced Patients with HIV-1 Infection

B. Clotet, D. Cooper, R. Steigbigel, 2015, Antiviral therapy.

Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.

Richard D Moore, J. Goedert, E. Moodie, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy

J. Mellors, R. Bosch, A. Collier, 2020, The Journal of Infectious Diseases.

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

R. Koup, J. Mellors, J. Coffin, 2017, The Journal of infectious diseases.

A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.

R. Haubrich, W. Snowden, J. Eron, 2001, Journal of acquired immune deficiency syndromes.

Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.

Richard D Moore, J. Robins, M. Hernán, 2016, International journal of epidemiology.

Selection Bias Due to Loss to Follow Up in Cohort Studies.

S. Cole, B. Lau, J. Eron, 2016, Epidemiology.

Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks

J. Montaner, B. Clotet, D. Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

B. Clotet, C. Katlama, J. Gatell, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Brief Report: Insomnia and Risk of Myocardial Infarction Among People With HIV

Richard D Moore, M. Budoff, S. Heckbert, 2022, Journal of acquired immune deficiency syndromes.

Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework

Richard D Moore, S. Cole, B. Lau, 2018, American journal of epidemiology.

Health Insurance Type and Control of Hypertension Among US Women Living With and Without HIV Infection in the Women’s Interagency HIV Study

S. Cole, A. Adimora, K. Anastos, 2017, American journal of hypertension.

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV

P. Sax, K. Mounzer, J. Eron, 2020, PloS one.

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.

T. Pilot‐Matias, J. Slim, J. Eron, 2015, JAMA.

Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

Richard D Moore, R. Hogg, S. Gange, 2007, International journal of epidemiology.

HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?

M. Weinstein, R. Walensky, K. Freedberg, 2014, PloS one.

HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico

M. Lederman, D. Podzamczer, D. Kuritzkes, 2015, Journal of the International AIDS Society.

HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.

J. Bartlett, A. Phillips, A. Hill, 1996, AIDS.

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

J. Montaner, B. Clotet, D. Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Variability of the date of HIV diagnosis: a comparison of self-report, medical record, and HIV/AIDS surveillance data.

W. Miller, S. McCoy, J. Eron, 2010, Annals of epidemiology.

Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008-2015.

Richard D Moore, A. Westfall, J. Willig, 2020, Progress in cardiovascular diseases.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

B. Walker, D. Kuritzkes, J. Martinez-Picado, 2019, The lancet. HIV.

Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients

Richard D Moore, S. Cole, J. Eron, 2017, PloS one.

Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort.

Richard D Moore, S. Cole, K. Richards, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort

Ann M. Dennis, A. Virkud, W. Miller, 2019 .

Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America

Richard D Moore, J. Goedert, B. Lau, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Potential Impact of Antiretroviral Therapy and Screening on Cervical Cancer Mortality in HIV-Positive Women in Sub-Saharan Africa: A Simulation

A. Adimora, E. Myers, W. Miller, 2011, PloS one.

Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.

Richard D Moore, J. Robins, M. Hernán, 2017, The lancet. HIV.

Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Sally S Bebawy, Richard D Moore, J. Margolick, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.

Richard D Moore, Ashley L. Buchanan, S. Cole, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort.

Ann M. Dennis, J. Eron, A. Seña, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hepatic Safety and Tolerability of Raltegravir among HIV Patients Coinfected with Hepatitis B And/Or C

Richard D Moore, J. Eron, C. Hurt, 2014, Antiviral therapy.

Invasive Cervical Cancer Risk Among HIV-Infected Women: A North American Multicohort Collaboration Prospective Study

Richard D Moore, J. Goedert, R. Hogg, 2013, Journal of acquired immune deficiency syndromes.

Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center

S. Carson, J. Parr, Casey A. Rimland, 2020, medRxiv.

A brief mental health and substance abuse screener for persons with HIV.

M. Swartz, K. Whetten, J. Eron, 2005, AIDS patient care and STDs.

Short communication: lack of occult HIV infection among non-AIDS-defining cancer patients in three academic oncology clinics in the United States.

M. Saag, S. Shrestha, J. Eron, 2013, AIDS research and human retroviruses.

Phylogenetic insights into regional HIV transmission

Ann M. Dennis, D. Pillay, J. Eron, 2012, AIDS.

Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.

D. Waters, J. Eron, D. Wohl, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.

D. Kuritzkes, R. D’Aquila, E. Acosta, 2001, The Journal of infectious diseases.

Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race–ethnicity determine the degree of regimen complexity

R. Haubrich, K. Tashima, V. Johnson, 2015, HIV clinical trials.

Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study

D. Kuritzkes, S. Swindells, J. Castro, 2013, Journal of acquired immune deficiency syndromes.

Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy.

M. Lederman, D. Kuritzkes, C. Rinaldo, 2013, The Journal of antimicrobial chemotherapy.

Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study

M. Hudgens, J. Eron, D. Wohl, 2012, Antimicrobial Agents and Chemotherapy.

How clean was the KLEAN trial? – Authors' reply

J. Eron, M. Shaefer, 2006, The Lancet.

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events

M. Ritchie, P. Sax, D. Haas, 2018, Pharmacogenetics and genomics.

Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077.

Myron S. Cohen, J. Currier, J. Eron, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy

Jessie K. Edwards, Richard D Moore, S. Cole, 2021, AIDS.

Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings.

Richard D Moore, C. Johannes, M. Mugavero, 2017, Journal of acquired immune deficiency syndromes.

HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015

Richard D Moore, B. Lau, I. Wilson, 2018, Annals of Internal Medicine.

Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March–December 2020

Richard D Moore, M. Saag, A. Webel, 2022, Journal of acquired immune deficiency syndromes.

Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States

M. Saag, B. Whitney, J. Eron, 2022, AIDS.

Brief Report: Differences in Types of Myocardial Infarctions Among People Aging With HIV.

Richard D Moore, M. Budoff, S. Heckbert, 2021, Journal of acquired immune deficiency syndromes.

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.

Richard D Moore, J. Goedert, Jeffrey N. Martin, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Elevated AST‐to‐platelet ratio index is associated with increased all‐cause mortality among HIV‐infected adults in Zambia

B. Chi, M. Vinikoor, G. Wandeler, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Entry and Fusion Inhibitors: an Update

John Moore, C. Hogan, C. Cohen, 2002 .

Brief Report: Longitudinal Opioid Use Among HIV-Infected Patients, 2000 to 2014

J. Eron, P. Leone, S. Napravnik, 2017, Journal of acquired immune deficiency syndromes.

Current and Past Immunodeficiency are Associated with Higher Hospitalization Rates among Persons on Virologically Suppressive Antiretroviral Therapy for up to Eleven Years.

Richard D Moore, Jennifer S. Lee, S. Cole, 2020, The Journal of infectious diseases.

Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy.

Richard D Moore, S. Cole, A. Olshan, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

Myron S. Cohen, C. Hendrix, M. Marzinke, 2018, PLoS medicine.

Expression of p16INK4a as a biomarker of T‐cell aging in HIV‐infected patients prior to and during antiretroviral therapy

M. Hudgens, N. Sharpless, J. Nelson, 2012, Aging cell.

Evolution of HIV-1 Drug Resistance after Virological Failure of First-line Antiretroviral Therapy in Lusaka, Zambia

B. Chi, J. Stringer, A. Westfall, 2019, Antiviral therapy.

Antiretroviral Therapy for the Prevention of HIV-1 Transmission.

J. Gallant, S. Swindells, I. Hoffman, 2016, The New England journal of medicine.

Impact of abstinence and of reducing illicit drug use without abstinence on HIV viral load.

Richard D Moore, R. Kronmal, C. del Rio, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Aciclovir treatment for human immunodeficiency virus-1: is the “juice worth the squeeze?”.

Myron S. Cohen, J. Eron, M. Cohen, 2011, Sexually transmitted diseases.

Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care

W. Miller, J. Eron, S. Napravnik, 2006, AIDS.

Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic

S. Carson, J. Parr, Casey A. Rimland, 2021, Healthcare.

Associations between female birth sex and risk of chronic kidney disease development among people with HIV in the USA: A longitudinal, multicentre, cohort study

M. Saag, P. MacLennan, J. Eron, 2022, EClinicalMedicine.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.

P. Volberding, H. Günthard, S. Buchbinder, 2020, JAMA.

Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates.

M. Hudgens, R. Baric, Myron S. Cohen, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ten Years of Screening and Testing for Acute HIV Infection in North Carolina

W. Miller, D. Margolis, J. Eron, 2016, Journal of acquired immune deficiency syndromes.

Incident sexually transmitted infection as a biomarker for high risk sexual behavior following diagnosis with acute HIV

J. Eron, C. Hicks, A. Cope, 2014 .

Hospitalization Rates and Outcomes Among Persons Living With Human Immunodeficiency Virus in the Southeastern United States, 1996–2016

J. Eron, S. Napravnik, Thibaut Davy-Mendez, 2020 .

Associations between drug and alcohol use, smoking, and frailty among people with HIV across the United States in the current era of antiretroviral treatment.

S. Kritchevsky, S. Austad, M. Saag, 2022, Drug and alcohol dependence.

An HIV Self-Care Symptom Management Intervention for African American Mothers

C. Pedersen, J. Eron, D. Holditch-Davis, 2003, Nursing research.

Paradoxical interpretations of noninferiority studies: violating the excluded middle

J. Eron, R. Lupinacci, M. Dinubile, 2012 .

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

P. Volberding, J. Gallant, M. Saag, 2002, AIDS research and human retroviruses.

Prevention of HIV-1 infection with early antiretroviral therapy.

Lei Wang, David Burns, Kenneth H Mayer, 2011, The New England journal of medicine.

Virologic outcomes in early antiretroviral treatment: HPTN 052

J. Gallant, Myron S. Cohen, K. Mayer, 2017, HIV clinical trials.

Randomized Controlled Pilot Study of Antiretrovirals and a Behavioral Intervention for Persons With Acute HIV Infection: Opportunity for Interrupting Transmission

Ann M. Dennis, W. Miller, C. Golin, 2018, Open forum infectious diseases.

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.

T. Holtz, C. del Rio, E. Daar, 2021, The New England journal of medicine.

Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials

J. Bartlett, J. Eron, G. E. Pakes, 1999, Antimicrobial Agents and Chemotherapy.

Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation

J. Eron, C. Hicks, S. Napravnik, 2018, Journal of acquired immune deficiency syndromes.

HIV and the Heart

J. Eron, K. Patterson, 2010 .

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

B. Clotet, J. Gatell, D. Cooper, 2013, The Lancet. Infectious diseases.

Advances in antiretroviral therapy

J. Eron, J. Arribas, 2013, Current opinion in HIV and AIDS.

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

K. Mounzer, K. Squires, L. Bekker, 2013, AIDS research and human retroviruses.

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

J. Eron, M. Rizk, J. Zhao, 2012, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of lamivudine administered alone and with trimethoprim‐sulfamethoxazole

J. Eron, E. Hussey, R. Raasch, 1996, Clinical pharmacology and therapeutics.

Frequent detection of acute primary HIV infection in men in Malawi

William C Miller, Christopher D Pilcher, W. Miller, 2004, AIDS.

HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors

R. Haubrich, K. Tashima, V. Johnson, 2015, Annals of Internal Medicine.

Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial

J. Gallant, Myron S. Cohen, K. Mayer, 2016, Journal of acquired immune deficiency syndromes.

Total daily pill burden in HIV-infected patients in the southern United States.

Shuntai Zhou, J. Eron, D. Wohl, 2014, AIDS patient care and STDs.

Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study.

Richard D Moore, T. Sterling, J. Eron, 2013, AIDS research and human retroviruses.

Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013.

J. Eron, S. Napravnik, N. L. Okeke, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hospitalization Rates and Causes among Persons with HIV in the US and Canada, 2005-2015.

Richard D Moore, Jennifer S. Lee, Jeffrey N. Martin, 2020, The Journal of infectious diseases.

Emergence of Dual Resistance to Zidovudine and Lamivudine in HIV‐1‐Infected Patients Treated With Zidovudine Plus Lamivudine as Initial Therapy

T. Gingeras, D. Kuritzkes, J. Eron, 2000, Journal of acquired immune deficiency syndromes.

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

M. Hughes, E. Daar, Davey M. Smith, 2022, Cell reports. Medicine.

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial

A. Perelson, S. Pedersen, R. Ribeiro, 2022, Nature Microbiology.

Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-week Results of AIDS Clinical Trials Group A5241 (OPTIONS).

K. Tashima, C. Fichtenbaum, L. Smeaton, 2019, The Journal of infectious diseases.

Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy : 96-week Results of AIDS Clinical Trials Group A 5241 ( OPTIONS )

K. Tashima, C. Fichtenbaum, --Manuscript Draft, 2019 .

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Karen L. Price, A. Perelson, R. Ribeiro, 2022, Nature Communications.

The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).

E. Acosta, R. Murphy, J. Gerber, 2002, The Journal of infectious diseases.

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Peter Reiss, Paul A Volberding, S. Hammer, 2008, JAMA.

Immunosuppression, Hepatitis C Infection, and Acute Renal Failure in HIV-Infected Patients

L. Szczech, N. Franceschini, J. Eron, 2006, Journal of acquired immune deficiency syndromes.

Eff ects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection : results from the phase 3 HPTN 052 randomised controlled trial

D. Havlir, J. Gallant, S. Swindells, 2014 .

Ending the evidence gap for pregnancy, HIV and co‐infections: ethics guidance from the PHASES project

B. Chi, L. Myer, L. Mofenson, 2021, Journal of the International AIDS Society.

Opioid misuse among persons with HIV engaged in care in the Southeastern US

J. Eron, S. Napravnik, Asher J Schranz, 2019, AIDS care.

Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19

E. Daar, C. Moser, J. Currier, 2022, Open forum infectious diseases.

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

M. Das, J. Lelièvre, J. Slim, 2019, The lancet. HIV.

Faculty Opinions recommendation of Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples.

J. Eron, C. Hurt, 2012 .

Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses

A. Sette, E. Daar, S. Crotty, 2022, JCI insight.

Pneumocystis and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Case Report and Review of an Emerging Diagnostic Dilemma

J. Parr, J. Eron, Asher J Schranz, 2020, Open forum infectious diseases.

Clinical and Behavioral Outcomes for Transgender Women Engaged in HIV Care: Comparisons to Cisgender Men and Women in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort

S. Reisner, M. Mugavero, K. Mayer, 2023, AIDS and Behavior.

1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis

D. Asmuth, J. Slim, J. Eron, 2020, Open Forum Infectious Diseases.

End-stage renal disease among HIV-infected adults in North America.

Richard D Moore, M. Gill, R. Bosch, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1

P. Vernazza, I. Hoffman, Myron S. Cohen, 1997, The Lancet.

Intracellular Nucleoside Triphosphate Concentrations in HIV-Infected Patients on Dual Nucleoside Reverse Transcriptase Inhibitor Therapy

V. Johnson, D. Kuritzkes, M. Fischl, 2007, Antiviral therapy.

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.

D. Richman, D. Havlir, J. Mellors, 1998, JAMA.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

M A Fischl, M D Hughes, S. Hammer, 1997, The New England journal of medicine.

Viral and Symptom Rebound in Untreated COVID-19 Infection

E. Daar, Davey M. Smith, C. Moser, 2022, medRxiv.

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

Cameron R. Wolfe, R. Baric, Myron S. Cohen, 2021, Science Translational Medicine.

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Huldrych F. Günthard, Amalio Telenti, Douglas D. Richman, 2012, JAMA.

Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy

Richard D Moore, Patrick A Ryscavage, B. Taiwo, 2013, AIDS.

HIV-1 protease inhibitors.

J. Eron, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection

M. Lederman, A. Zolopa, P. Grant, 2010, PloS one.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.

Jennifer F Hoy, Michael S Saag, Huldrych F Günthard, 2016, JAMA.

Comparative Effectiveness of Fish Oil Versus Fenofibrate, Gemfibrozil, and Atorvastatin on Lowering Triglyceride Levels Among HIV-Infected Patients in Routine Clinical Care

J. Kahn, J. Willig, M. Mugavero, 2013, Journal of acquired immune deficiency syndromes.

Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection: A North American Cross Cohort Analysis

Richard D Moore, J. Goedert, K. Anastos, 2013, Journal of acquired immune deficiency syndromes.

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients

D. Kuritzkes, J. Eron, J. Eron, 1996, AIDS.

Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1

J. Eron, J. Eron, A. Kashuba, 1999, Antimicrobial Agents and Chemotherapy.

Virus Type 1 Transmission of Human Immunodeficiency Semen : Implications for Sexual Antiretroviral-Drug Concentrations in

J. Eron, A. Kashuba, J. Dyer, 1999 .

Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter

D. Kuritzkes, J. Eron, R. MacArthur, 1995 .

A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.

R. Wood, J. Eron, C. Trépo, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

H. Stellbrink, R. Wood, F. Raffi, 2004, Antimicrobial Agents and Chemotherapy.

Factors Associated With Delayed Hepatitis B Viral Suppression on Tenofovir Among Patients Coinfected With HBV-HIV in the CNICS Cohort

Richard D Moore, Jeffrey N. Martin, S. Boswell, 2014, Journal of acquired immune deficiency syndromes.

Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.

C. Flexner, R. Bosch, I. Frank, 2004, AIDS research and human retroviruses.

The treatment of antiretroviral‐naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials

J. Eron, 1996, AIDS.

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

Victor DeGruttola, Florin Vaida, S. Hammer, 2002, JAMA.

Factors Associated with Delayed Hepatitis B Viral Suppression on Tenofovir Among HBV-HIV Coinfected Patients in the CNICS Cohort

Jeffrey N. Martin, S. Boswell, M. Mugavero, 2014 .

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

D. Podzamczer, B. Clotet, H. Stellbrink, 2017, The Lancet.

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients.

D. Podzamczer, J. Rockstroh, C. Orkin, 2019, AIDS.

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

D. Kuritzkes, A. Caliendo, R. D’Aquila, 1999, The Journal of infectious diseases.

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

M. King, M. Witt, H. Kessler, 2004, The Journal of infectious diseases.

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.

C. Pettinelli, I. Marschner, V. Johnson, 1999, AIDS.

A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir

S. Hammer, J. Mellors, K. Squires, 2002, Antiviral therapy.

Simplifying antiretroviral therapy.

C. Flexner, J. Eron, M. Tapper, 2004, The AIDS reader.

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

C. Katlama, S. Staszewski, J. Eron, 2006, The Lancet.

Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?

J. Eron, C. Hurt, M. Cohen, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry.

J. Eron, R. Tidwell, J. Dunn, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Effect of antiviral treatment on the shedding of HIV‐1 in semen

P. Vernazza, J. Eron, S. Fiscus, 1997, AIDS.

Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370

C. Pettinelli, I. Marschner, V. Johnson, 2000, AIDS.

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

J. Eron, Kimberly Smith, W. Spreen, 2015, The Lancet. Infectious diseases.

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TA

C. Orkin, F. Post, S. De Wit, 2019, Antiviral research.

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

E. Negredo, J. Gallant, A. Antinori, 2018, AIDS.

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised,

E. Negredo, C. Orkin, J. Eron, 2018, The lancet. HIV.

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

Jing Zhao, Christine Katlama, Benjamin Young, 2011, The Lancet. Infectious diseases.

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

Jennifer F Hoy, Amalio Telenti, Michael S Saag, 2014, JAMA.

Attrition among Human Immunodeficiency Virus (HIV)- Infected Patients Initiating Antiretroviral Therapy in China, 2003–2010

S. Cole, J. Eron, D. Wohl, 2012, PloS one.

Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2

S. Cole, H. Chu, C. Poole, 2011, AIDS.

Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.

M. King, H. Kessler, R. Murphy, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Large scale screening of human sera for HCV RNA and GBV‐C RNA

R. Swanstrom, J. Eron, J. Keys, 2014, Journal of medical virology.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

Huldrych F. Günthard, Michael S. Saag, Joseph J. Eron, 2018, JAMA.

The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration.

M. Molyneux, T. Taylor, I. Hoffman, 1999, AIDS.

Moving forward in HIV-associated cancer.

D. Dittmer, E. Engels, C. Achenbach, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

S. Hammer, D. Katzenstein, S. Liou, 2001, The New England journal of medicine.

The Relationship Between Efavirenz as Initial Antiretroviral Therapy and Suicidal Thoughts Among HIV-Infected Adults in Routine Care

Richard D Moore, M. Mugavero, J. Eron, 2017, Journal of acquired immune deficiency syndromes.

Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide

P. Sax, E. Daar, K. Robertson, 2014, Annals of Internal Medicine.

Antiretroviral Treatment of Adult HIV Infection

Douglas D. Richman, Julio S. G. Montaner, Peter Reiss, 2008 .

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.

C. Hendrix, M. Marzinke, J. Eron, 2020, The lancet. HIV.

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077

M. Siegel, E. Tolley, J. Eron, 2020, AIDS and Behavior.

Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men.

J. Eron, J. Eron, S. Gotzkowsky, 2002, The Journal of infectious diseases.

Incidence and etiology of acute renal failure among ambulatory HIV-infected patients.

L. Szczech, N. Franceschini, J. Eron, 2005, Kidney international.

Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48-Week Analysis

B. Clotet, J. Eron, V. van Eygen, 2012, Journal of acquired immune deficiency syndromes.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

D. Cooper, M. Youle, R. Leavitt, 2010, The Lancet.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.

H. Günthard, S. Buchbinder, P. Sax, 2022, JAMA.

Resistance of HIV‐1 to antiretroviral agents in blood and seminal plasma: implications for transmission

P. Vernazza, J. Eron, S. Fiscus, 1998, AIDS.

Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviral—Naïve HIV-1-Infected Patients

M. King, S. Brun, R. Murphy, 2008, HIV clinical trials.

Persistent Antiretroviral Activity of Nucleoside Analogues After Prolonged Zidovudine and Lamivudine Therapy as Demonstrated by Rapid Loss of Activity After Discontinuation

V. Johnson, D. Kuritzkes, J. Bartlett, 2004, Journal of acquired immune deficiency syndromes.

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

Joel E Gallant, Calvin Cohen, Edwin DeJesus, 2003, AIDS.

Reductions in HIV‐1 disease progression for zidovudine/lamivudine relative to control treatments: a meta‐analysis of controlled trials

C. Katlama, J. Bartlett, S. Staszewski, 1997, AIDS.

Predictive Value of Pharmacokinetics-Adjusted Phenotypic Susceptibility on Response to Ritonavir-Enhanced Protease Inhibitors (PIs) in Human Immunodeficiency Virus-Infected Subjects Failing Prior PI Therapy

R. Haubrich, D. Richman, J. Park, 2009, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic Study of Human Immunodeficiency Virus Protease Inhibitors Used in Combination with Amprenavir

R. Haubrich, B. Sadler, J. Eron, 2001, Antimicrobial Agents and Chemotherapy.

Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy

J. Eron, J. Keruly, S. Napravnik, 2007, HIV medicine.

Discontinuation Rates for Protease Inhibitor Regimens Containing Ritonavir 600 mg versus Ritonavir 400 mg Plus Saquinavir 400 mg

J. Eron, J. Butts, R. Raasch, 1999, The Annals of pharmacotherapy.

Genetic architecture of cardiometabolic risks in people living with HIV

Richard D Moore, K. Hao, P. Crane, 2020, BMC Medicine.

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

A. LaMarca, B. Clotet, C. Katlama, 2012, The Journal of infectious diseases.

Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection

E. Daar, C. Moser, J. Currier, 2023, Annals of Internal Medicine.

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)*

D. Peterson, S. Swindells, R. Murphy, 2000, AIDS.

Effect of early versus deferred antiretroviral therapy for HIV on survival.

Michael J Silverberg, Bryan Lau, Michael S Saag, 2009, The New England journal of medicine.

Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients

J. Eron, A. Landay, D. Mildvan, 2004, HIV medicine.

The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment

J. McCarthy, S. Meshnick, A. Siika, 2012, PloS one.

HIV-1 Protease Inhibitors and Clinical Malaria: a Secondary Analysis of the AIDS Clinical Trials Group A5208 Study

S. Cole, M. Hughes, J. McCarthy, 2011, Antimicrobial Agents and Chemotherapy.

Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.

R. Haubrich, D. Kuritzkes, B. Taiwo, 2011, The Journal of infectious diseases.

Systemically Circulating Viral and Tumor-Derived MicroRNAs in KSHV-Associated Malignancies

Pauline E. Chugh, J. Griffith, D. Dittmer, 2013, PLoS pathogens.

Macrophages sustain HIV replication in vivo independently of T cells.

A. Haase, J. Garcia, V. Madden, 2016, The Journal of clinical investigation.

Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010.

K. Richards, J. Eron, S. Gopal, 2012, AIDS research and human retroviruses.

Prevalence of DSM-IV-Defined Mood, Anxiety, and Substance Use Disorders in an HIV Clinic in the Southeastern United States

W. Miller, B. Gaynes, K. Whetten, 2006, Journal of acquired immune deficiency syndromes.

High Levels of Antiretroviral Use and Viral Suppression Among Persons in HIV Care in the United States, 2010

Richard D Moore, M. Golden, Jeffrey N. Martin, 2013, Journal of acquired immune deficiency syndromes.

Not all non-drinkers with HIV are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disorders*

Richard D Moore, B. Lau, M. Mimiaga, 2017, AIDS care.

HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays.

J. Eron, P. Stewart, S. Fiscus, 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Viral suppression in HIV studies: Combining times to suppression and rebound

S. Cole, J. Fine, J. Eron, 2014, Biometrics.

Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.

Richard D Moore, S. Cole, B. Lau, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.

S. Cole, B. Lau, M. Mugavero, 2010, American journal of epidemiology.

Gender Difference in HIV RNA Levels: A Meta‐Analysis of Published Studies

C. Poole, J. Eron, S. Napravnik, 2002, Journal of acquired immune deficiency syndromes.

Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis

S. Hammer, D. Katzenstein, R. Schooley, 2000 .

HIV-1 Drug Resistance Evolution Among Patients on Potent Combination Antiretroviral Therapy With Detectable Viremia

D. Edwards, J. Eron, P. Stewart, 2005, Journal of acquired immune deficiency syndromes.

Ongoing HIV Transmission and the HIV Care Continuum in North Carolina

L. Ping, R. Swanstrom, W. Miller, 2015, PloS one.

Novel Criteria for Diagnosing Acute and Early HIV Infection in a Multi-National Study of Early Antiretroviral Therapy Initiation.

B. Chi, J. Ananworanich, K. Ruxrungtham, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Using Primer-ID Deep Sequencing to Detect Recent Human Immunodeficiency Virus Type 1 Infection

Ann M. Dennis, Shuntai Zhou, R. Swanstrom, 2018, The Journal of infectious diseases.

Amendment history : Corrigendum ( December 2006 ) Acute HIV revisited : new opportunities for treatment and prevention

J. Eron, C. Pilcher, S. Galvin, 2018 .

The Detection and Management of Early HIV Infection: A Clinical and Public Health Emergency

W. Miller, J. Eron, S. Rutstein, 2013, Journal of acquired immune deficiency syndromes.

Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4+ T Cells

John M. Coffin, William Ince, R. Swanstrom, 2011, Journal of Virology.

High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men

Alan S. Perelson, Hui Li, Tanmoy Bhattacharya, 2010, PLoS pathogens.

Detection of acute infections during HIV testing in North Carolina.

William C Miller, Trang Q Nguyen, Christopher D Pilcher, 2005, The New England journal of medicine.

Acute HIV revisited: new opportunities for treatment and prevention.

J. Eron, C. Pilcher, S. Galvin, 2004, The Journal of clinical investigation.

Rising prevalence of non-B HIV-1 subtypes in North Carolina and evidence for local onward transmission

Ann M. Dennis, W. Miller, J. Eron, 2017, Virus evolution.

Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy

Guido Ferrari, Hui Li, David Margolis, 2011, PloS one.

Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.

J. Eron, C. Hurt, C. Hicks, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States

Sally S Bebawy, Richard D Moore, Jennifer S. Lee, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens

Richard D Moore, S. Cole, M. Mugavero, 2017, AIDS.

Illustration of a Measure to Combine Viral Suppression and Viral Rebound in Studies of HIV Therapy

S. Cole, A. Adimora, J. Fine, 2015, Journal of acquired immune deficiency syndromes.

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

S. Hammer, M. Saag, A. Collier, 2003, The Journal of infectious diseases.

Outpatient Treatment of SARS-CoV-2 Infection to Prevent COVID-19 Progression

J. Eron, D. Wohl, W. Fischer, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Outpatient Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection to Prevent Coronavirus Disease 2019 Progression

Davey M. Smith, J. Eron, D. Wohl, 2021, Clinical Infectious Diseases.

Associations between alcohol and cigarette use and type 1 and 2 myocardial infarction among people with HIV

M. Budoff, S. Heckbert, M. Saag, 2023, HIV medicine.

Novel therapies based on mechanisms of HIV-1 cell entry.

J. Kilby, J. Eron, J. Eron, 2003, The New England journal of medicine.

Prevalence and Comorbidity of Psychiatric Diagnoses Based on Reference Standard in an HIV+ Patient Population

W. Miller, B. Gaynes, J. Eron, 2008, Psychosomatic medicine.

Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome

J. Tolson, N. Graham, J. Eron, 2001, Advances in therapy.

Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors

J. Eron, S. Napravnik, C. Gay, 2006, AIDS.

Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification

Mark J van der Laan, Maya L Petersen, Richard D Moore, 2008, AIDS.

Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation

Richard D Moore, Jennifer S. Lee, S. Cole, 2017, AIDS.

Patterns of Efavirenz use as First-Line Antiretroviral Therapy in the United States: 1999–2015

Richard D Moore, M. Mugavero, E. Geng, 2018, Antiviral therapy.

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

D. Kuritzkes, E. Acosta, B. Taiwo, 2011, AIDS.

Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients

J. Eron, D. Wohl, J. Keys, 2007, AIDS.

Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals

Hulin Wu, Song Yu, Edward P Acosta, 2004, Journal of acquired immune deficiency syndromes.

Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm

J. Mellors, M. Weinberger, W. Miller, 2016, BMC Infectious Diseases.

Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems

Richard D Moore, M. Budoff, D. Lloyd‐Jones, 2017, JAMA cardiology.

Near Real-Time Identification of Recent HIV Transmissions, Transmitted Drug Resistance Mutations, and Transmission Networks by MPID-NGS in North Carolina.

Ann M. Dennis, Shuntai Zhou, Corbin D. Jones, 2020, The Journal of infectious diseases.

Psychiatric Illness and Virologic Response in Patients Initiating Highly Active Antiretroviral Therapy

W. Miller, B. Gaynes, J. Eron, 2007, Journal of acquired immune deficiency syndromes.

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

Kenneth H Mayer, Ian Sanne, Max Essex, 2014, The Lancet. Infectious diseases.

Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.

B. Taiwo, J. Eron, C. Hicks, 2010, The Journal of antimicrobial chemotherapy.

HIV Care Initiation Delay Among Rural Residents in the Southeastern United States, 1996 to 2012

M. Mugavero, W. Miller, J. Eron, 2017, Journal of acquired immune deficiency syndromes.

Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada.

Richard D Moore, B. Lau, K. Buchacz, 2016, AIDS research and human retroviruses.

Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population

Richard D Moore, M. Budoff, Jeffrey N. Martin, 2017, Journal of acquired immune deficiency syndromes.

Types of Myocardial Infarction Among Human Immunodeficiency Virus–Infected Individuals in the United States

Richard D Moore, M. Budoff, J. Willig, 2017, JAMA cardiology.

Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts.

M. Budoff, J. Willig, J. A. Delaney, 2014, American journal of epidemiology.

Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia.

B. Chi, J. Stringer, M. Vinikoor, 2014, AIDS research and human retroviruses.

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

S. Hammer, A. Hsu, M. King, 2001, AIDS.

Late presentation for human immunodeficiency virus care in the United States and Canada.

Richard D Moore, J. Goedert, Jeffrey N. Martin, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Anal cancer incidence in men with HIV who have sex with men: are black men at higher risk?

Richard D Moore, Jennifer S. Lee, S. Cole, 2021, AIDS (London).

Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy

Richard D Moore, Jennifer S. Lee, S. Cole, 2018, PloS one.

HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers

Richard D Moore, J. Goedert, R. Pfeiffer, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States.

Richard D Moore, S. Cole, M. Ballestas, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence

Richard D Moore, S. Cole, A. Olshan, 2014, AIDS.

Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011

D. Dittmer, B. Damania, J. Eron, 2013, Infectious Agents and Cancer.

Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015.

Richard D Moore, S. Cole, M. Gill, 2021, AIDS.

Hospitalization Rates and Outcomes among Persons Living with HIV in the Southeastern United States, 1996-2016.

J. Eron, D. Wohl, Claire E Farel, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence and Factors Associated with Hazardous Alcohol Use Among Persons Living with HIV Across the US in the Current Era of Antiretroviral Treatment

B. Lau, M. Mimiaga, J. Willig, 2017, AIDS and Behavior.

Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis

Richard D Moore, S. Boswell, M. Saag, 2016, Journal of acquired immune deficiency syndromes.

Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.

Richard D Moore, S. Cole, K. Richards, 2013, Journal of the National Cancer Institute.

Postpartum HIV care continuum outcomes in the southeastern USA

J. Eron, B. Pence, Claire E Farel, 2019, AIDS.

The Role of Current and Historical Alcohol Use in Hepatic Fibrosis Among HIV-Infected Individuals

Richard D Moore, M. Mugavero, M. Saag, 2017, AIDS and Behavior.

American Journal of Epidemiology Practice of Epidemiology Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated with Antiretroviral Drugs in North America

Richard D Moore, J. Goedert, B. Lau, 2022 .

Association of early HIV viremia with mortality after HIV-associated lymphoma

Richard D Moore, S. Cole, K. Richards, 2013, AIDS.

Effects of Health Insurance Interruption on Loss of Hypertension Control in Women With and Women Without HIV.

Denise D. Krause, S. Cole, Mardge H. Cohen, 2017, Journal of women's health.

Risk of End‐Stage Renal Disease in HIV‐Positive Potential Live Kidney Donors

L. Kucirka, S. Boswell, M. Gill, 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

R5 Macrophage-Tropic HIV-1 in the Male Genital Tract

Shuntai Zhou, L. Ping, R. Swanstrom, 2015, Journal of Virology.

Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections

K. Anastos, M. Young, G. Lauer, 2016, Genes and Immunity.

Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies.

Richard D Moore, K. Anastos, S. Gange, 2019, The lancet. HIV.

Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance

Hulin Wu, Edward P Acosta, Daniel R Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007.

S. Cole, J. Eron, C. Howe, 2010, AIDS research and human retroviruses.

Age trends in the prevalence of cervical squamous intraepithelial lesions among HIV-positive women in Cameroon: a cross-sectional study

A. Adimora, E. Myers, W. Miller, 2012, BMC Research Notes.

Weight gain following antiretroviral therapy (ART) initiation in ART-naïve people living with HIV in the current treatment era.

Brian R Wood, S. Lindström, M. Saag, 2020, Journal of acquired immune deficiency syndromes.

Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV

Richard D Moore, S. Gange, T. Sterling, 2018, Journal of acquired immune deficiency syndromes.

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants

M. Hudgens, R. Haubrich, P. Sax, 2017, The Journal of infectious diseases.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy

J. Mellors, R. Bosch, A. Danesh, 2021, JCI insight.

Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy.

J. Siliciano, J. Mellors, R. Bosch, 2020, The Journal of infectious diseases.

Curing HIV: Seeking to Target and Clear Persistent Infection

R. Swanstrom, D. Margolis, G. Ferrari, 2020, Cell.

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Nancie M Archin, Ronald J Bosch, R. Bosch, 2015, The Journal of infectious diseases.

Types of Stroke Among People Living With HIV in the United States.

Richard D Moore, Rizwan Kalani, J. A. Delaney, 2021, Journal of acquired immune deficiency syndromes.

T cells establish and maintain CNS viral infection in HIV‐infected humanized mice

B. Liao, M. Swanson, J. Garcia, 2018, The Journal of clinical investigation.

Tobacco smoking and binge alcohol use are associated with incident venous thromboembolism in an HIV cohort

M. Budoff, S. Heckbert, M. Saag, 2022, HIV medicine.

Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection

John M. Coffin, Ronald J. Bosch, J. Coffin, 2010, PloS one.

No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

R. Siliciano, J. Siliciano, R. Bosch, 2010, The Journal of infectious diseases.

Sexually transmitted infections among patients with acute HIV in North Carolina.

W. Miller, S. McCoy, J. Eron, 2009, Sexually transmitted diseases.

Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis.

Richard D Moore, Ashleigh J. Rich, S. Reisner, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model.

D. Westreich, F. Behets, J. Eron, 2007, The Journal of infectious diseases.

Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors.

Richard D Moore, M. Budoff, S. Heckbert, 2018, AIDS research and human retroviruses.

HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients

S. Hammer, J. Falloon, H. Masur, 2002, AIDS.

Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies

C. Hung, J. Slim, J. Eron, 2019, Journal of Infection and Public Health.

Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV

R. Steigbigel, H. Teppler, J. Rockstroh, 2010, Journal of the International AIDS Society.

Beyond core indicators of retention in HIV care: missed clinic visits are independently associated with all-cause mortality.

Richard D Moore, S. Cole, A. Westfall, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Influence of Substance Use Disorders on 2-Year HIV Care Retention in the United States

Richard D Moore, M. Mugavero, K. Mayer, 2018, AIDS and Behavior.

Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States

M. Mugavero, K. Mayer, Bryan Hartzler, 2017, AIDS and Behavior.

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation

R. Shafer, M. Winters, S. Holmes, 2016, Journal of Virology.

Social Network–Based Recruitment Successfully Reveals HIV-1 Transmission Networks Among High-Risk Individuals in El Salvador

Ann M. Dennis, J. Eron, G. Paz-Bailey, 2013, Journal of acquired immune deficiency syndromes.

Factors associated with fewer visits for HIV primary care at a tertiary care center in the SoutheAstern U.S.

J. Eron, P. Menezes, S. Napravnik, 2006, AIDS care.

Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care

Richard D Moore, B. Lau, Jeffrey N. Martin, 2012, AIDS.

Ten-year Survival by Race/Ethnicity and Sex Among Treated, HIV-infected Adults in the United States.

Jessie K. Edwards, Richard D Moore, S. Cole, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Leveraging Phylogenetics to Understand HIV Transmission and Partner Notification Networks

Ann M. Dennis, I. Doherty, W. Miller, 2018, Journal of acquired immune deficiency syndromes.

Splines for trend analysis and continuous confounder control.

S. Cole, S. Greenland, D. Westreich, 2011, Epidemiology.

Association between bilirubin, atazanavir, and cardiovascular disease events among people living with HIV across the US.

Brian R Wood, Richard D Moore, M. Budoff, 2019, Journal of Acquired Immune Deficiency Syndromes.

Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings

S. Cole, A. Adimora, J. Eron, 2019, Epidemiology.

US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials.

S. Cole, A. Adimora, J. Eron, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.

T. Gingeras, D. Kuritzkes, J. Eron, 2000 .

Alternative strategies for anti-HIV treatment.

P. Vernazza, J. Eron, 2001, AIDS.

Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.

J. Eron, S. Fiscus, O. Naderer, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.

P. Sax, A. Hsu, D. Kempf, 2002, The Journal of infectious diseases.

Neurocognition with maraviroc compared with tenofovir in HIV

K. Robertson, B. Taiwo, T. Brown, 2016, AIDS.

CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?

Richard D Moore, J. Goedert, Jeffrey N. Martin, 2010, AIDS research and therapy.

Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years.

Richard D Moore, S. Cole, K. Buchacz, 2021, Journal of Infectious Diseases.

Evaluating the incident user design in the HIV population: incident use versus naive?

D. Moga, J. Eron, S. Napravnik, 2015, Pharmacoepidemiology and drug safety.

Decreasing Excess Mortality of HIV-Infected Patients Initiating Antiretroviral Therapy: Comparison with Mortality in General Population in China, 2003–2009

S. Cole, J. Eron, D. Wohl, 2013, Journal of acquired immune deficiency syndromes.

Perceived oral health status, unmet needs, and barriers to dental care among HIV/AIDS patients in a North Carolina cohort: impacts of race.

L. Patton, J. Eron, R. Strauss, 2007, Journal of public health dentistry.

HIV-specific T-cell responses reflect substantive in vivo interactions with infected cells despite long-term therapy

J. Mellors, R. Bosch, A. Danesh, 2020 .

Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection

E. Daar, C. Moser, J. Currier, 2023, Annals of Internal Medicine.

Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States.

M. Vinikoor, J. Eron, S. Napravnik, 2013, AIDS research and human retroviruses.

HIV risk behaviors and sociodemographic features of HIV-infected Latinos residing in a new Latino settlement area in the Southeastern United States

Ann M. Dennis, J. Eron, L. Hightow-Weidman, 2013, AIDS care.

Improving health outcomes among individuals with HIV, mental illness, and substance use disorders in the Southeast

M. Swartz, C. Conover, K. Whetten, 2006, AIDS care.

HIV Transmission Patterns Among Immigrant Latinos Illuminated by the Integration of Phylogenetic and Migration Data.

Ann M. Dennis, W. Miller, J. Eron, 2015, AIDS research and human retroviruses.

Joint effects of alcohol consumption and high-risk sexual behavior on HIV seroconversion among men who have sex with men

S. Cole, D. Ostrow, R. Bolan, 2013, AIDS.

New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations

Ann M. Dennis, J. Eron, S. Napravnik, 2018, AIDS.

Sexual transmission during the incubation period of primary HIV infection.

M. Battegay, S. Yerly, L. Perrin, 2001, JAMA.

Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS)

Richard D Moore, M. Budoff, D. Lloyd‐Jones, 2019, BMC Medicine.

HIV primary care providers--Screening, knowledge, attitudes and behaviors related to alcohol interventions.

Richard D Moore, S. Boswell, M. Saag, 2016, Drug and alcohol dependence.

Evaluating the Efficacy of Therapies in Patients With Coronavirus Disease 2019

D. Zeng, D. Lin, J. Eron, 2020, Clinical Infectious Diseases.

Evaluating the Efficacy of Therapies in Patients With Coronavirus Disease 2019

D. Zeng, D. Lin, J. Eron, 2020, Clinical Infectious Diseases.

How Researchers Define Vulnerable Populations in HIV/AIDS Clinical Trials

B. Lo, A. Gifford, J. Eron, 2010, Aids and Behavior.

High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: Is targeted screening feasible?

A. Adimora, E. Myers, W. Miller, 2012, Cancer epidemiology.

Drug and alcohol use among people living with HIV in care in the United States by geographic region

Richard D Moore, B. Lau, M. Mugavero, 2021, AIDS care.

Multiple Imputation to Account for Measurement Error in Marginal Structural Models

Jessie K. Edwards, Richard D Moore, S. Cole, 2015, Epidemiology.

Opportunities for sexual transmission of antiretroviral drug resistance among HIV-infected patients in care

J. Eron, C. Hurt, S. Napravnik, 2013, AIDS.

Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007

J. Nelson, S. McCoy, J. Eron, 2008, Antiviral therapy.

HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052

J. Gallant, J. Eron, M. Hosseinipour, 2017, Journal of acquired immune deficiency syndromes.

Loss to Clinic and Five-Year Mortality among HIV-Infected Antiretroviral Therapy Initiators

Richard D Moore, S. Cole, M. Mugavero, 2014, PloS one.

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials

D. Podzamczer, E. Negredo, H. Stellbrink, 2019, AIDS.

When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study

J. Robins, M. Hernán, S. Hernández-Díaz, 2016, Journal of acquired immune deficiency syndromes.

Mortality Among Persons Entering HIV Care Compared With the General U.S. Population

Jessie K. Edwards, Richard D Moore, S. Cole, 2021, Annals of Internal Medicine.

Validation of a Brief Screening Instrument for Substance Abuse and Mental Illness in HIV-Positive Patients

W. Miller, B. Gaynes, K. Whetten, 2005, Journal of acquired immune deficiency syndromes.

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

T. Merigan, G. D. Miralles, J. Bartlett, 2004, The Journal of infectious diseases.

Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States

Sally S Bebawy, Richard D Moore, K. Anastos, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals

Richard D Moore, J. Robins, M. Hernán, 2019, Statistics in medicine.

Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States.

Richard D Moore, S. Cole, M. Mugavero, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.

S. Cole, M. Davidian, J. Kaufman, 2011, Archives of internal medicine.

Emotional Distress in African American Women with HIV

T. Schwartz, C. Pedersen, J. Eron, 2007, Journal of prevention & intervention in the community.

Substance Abuse and Symptoms of Mental Illness Among HIV-positive Persons in the Southeast

M. Swartz, K. Whetten, J. Eron, 2005, Southern medical journal.

Associations Between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy Among Patients Living with HIV.

M. Mimiaga, J. Willig, P. Crane, 2017, AIDS research and human retroviruses.

Antiretroviral Activity and Safety of Once-Daily Etravirine in Treatment-Naive HIV-Infected Adults: 48-Week Results

J. Eron, D. Wohl, K. Mollan, 2016, Antiviral therapy.

The prevalence of mental health disorders in people with HIV and the effects on the HIV care continuum

P. Zandi, M. Horberg, P. Rebeiro, 2022, AIDS.

The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11.

S. Cole, M. Mugavero, W. Miller, 2016, International journal of epidemiology.

African American race and HIV virological suppression: beyond disparities in clinic attendance.

S. Cole, A. Adimora, J. Kaufman, 2014, American journal of epidemiology.

The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV(+) African Americans.

S. Cole, A. Adimora, J. Kaufman, 2014, AIDS research and human retroviruses.

Reply to P. De Paoli et al.

D. Dittmer, E. Engels, C. Achenbach, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HIV Viremia and Risk of Stroke Among People Living with HIV Who Are Using Antiretroviral Therapy

Richard D Moore, Rizwan Kalani, S. Heckbert, 2021, Epidemiology.

Cumulative Human Immunodeficiency Viremia, Antiretroviral Therapy, and Incident Myocardial Infarction

Richard D Moore, M. Budoff, S. Heckbert, 2019, Epidemiology.

Generalizing evidence from randomized trials using inverse probability of sampling weights

Michael G Hudgens, Stephen R Cole, Michael J Mugavero, 2018, Journal of the Royal Statistical Society. Series A,.

Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US.

A. Adimora, T. Sterling, M. Horberg, 2023, JAMA.

Increased Persistence of Initial Treatment for HIV Infection With Modern Antiretroviral Therapy

J. Eron, D. Wohl, S. Napravnik, 2017, Journal of acquired immune deficiency syndromes.

Effects of Combination Antiretroviral Therapies on the Risk of Myocardial Infarction Among HIV Patients

T. Stürmer, J. Eron, R. Simpson, 2014, Epidemiology.

Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy

O. Kirk, J. Montaner, A. Phillips, 2001, Antiviral therapy.

Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study

C. Katlama, J. Gatell, A. Lazzarin, 2010, Journal of acquired immune deficiency syndromes.

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection

M. Hughes, C. Fletcher, J. Currier, 2022, Clinical pharmacology and therapeutics.

Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay.

R. Bosch, I. Frank, J. Eron, 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Prediction of HIV Transmission Cluster Growth With Statewide Surveillance Data

Ann M. Dennis, W. Miller, J. Eron, 2019, Journal of acquired immune deficiency syndromes.

Prevalence and risk of residual viremia after ART in low- and middle-income countries

J. Lifson, K. Ruxrungtham, S. Kerr, 2021, Medicine.

Residual Plasma Viraemia and Infectious HIV-1 Recovery from Resting Memory CD4 Cells in Patients on Antiretroviral Therapy: Results from ACTG A5173

R. Siliciano, J. Siliciano, J. Mellors, 2013, Antiviral therapy.

Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.

V. Johnson, M. Saag, I. Frank, 2006, The Journal of infectious diseases.

Neighborhood Poverty and Control of HIV, Hypertension, and Diabetes in the Women’s Interagency HIV Study

S. Cole, Mardge H. Cohen, A. Adimora, 2020, AIDS and Behavior.

Significant decline in heavily treatment experienced persons with HIV with limited antiretroviral treatment options in the US, 2000-2017.

Richard D Moore, M. Saag, K. Mayer, 2020, AIDS.

Dose Separation Does Not Overcome the Pharmacokinetic Interaction between Fosamprenavir and Lopinavir/Ritonavir

J. Eron, A. Kashuba, H. Tien, 2006, Antimicrobial Agents and Chemotherapy.

Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects with Prior Nucleoside Analog Experience

S. Hammer, K. Squires, M. Fischl, 2008, HIV clinical trials.

High-Dose Lopinavir/Ritonavir in Highly Treatment-Experienced HIV-1 Patients: Efficacy, Safety, and Predictors of Response

D. Podzamczer, C. Katlama, D. Havlir, 2007, HIV clinical trials.

Reduction in cerebral oxygen metabolism in subcortical regions may be a biomarker of cognitive decline in people living with human immunodeficiency virus

H. An, W. Powers, S. Sen, 2021, European journal of neurology.

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.

J. Montaner, B. Clotet, D. Kuritzkes, 2007, AIDS patient care and STDs.

Comparing neighborhood and state contexts for women living with and without HIV: understanding the Southern HIV epidemic

S. Cole, Mardge H. Cohen, A. Adimora, 2018, AIDS care.

Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women's Interagency HIV Study, 2006–2009

S. Cole, Mardge H. Cohen, A. Adimora, 2016, Journal of acquired immune deficiency syndromes.

HIV-1 Transmission linkages among persons with incident infection to inform public health surveillance

Ann M. Dennis, E. Volz, S. Frost, 2021, EClinicalMedicine.

The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).

R. D’Aquila, J. Currier, R. Murphy, 2000, The Journal of infectious diseases.

Faculty Opinions recommendation of Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence.

J. Eron, C. Hurt, 2012 .

Social support and delays seeking care after HIV diagnosis, North Carolina, 2000–2006

W. Miller, S. McCoy, J. Eron, 2009, AIDS care.

Social support and delays seeking care after HIV diagnosis

W. Miller, S. McCoy, J. Eron, 2009 .

Racial and ethnic disparities in COVID-19 disease incidence independent of comorbidities, among people with HIV in the US

M. Saag, K. Mayer, B. Whitney, 2021, medRxiv.

Polygenic risk scores point toward potential genetic mechanisms of type 2 myocardial infarction in people with HIV.

J. Björkegren, P. Crane, S. Lindstrom, 2023, International journal of cardiology.

Chronic obstructive pulmonary disease and the risk for myocardial infarction by type in people with HIV

M. Budoff, S. Heckbert, M. Saag, 2022 .

Barriers and facilitators to HIV testing and linkage to primary care: narratives of people with advanced HIV in the Southeast

W. Miller, S. McCoy, J. Eron, 2009, AIDS care.

A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.

R. Haubrich, W. Snowden, J. Eron, 2001, Journal of acquired immune deficiency syndromes.

Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical Cohort

M. Brookhart, T. Stürmer, M. Vinikoor, 2015, Medical care.

Track C Epidemiology and Prevention Science

David R. Holtgrave, W. Heneine, Y. Nakamura, 2012, Journal of the International AIDS Society.

Chagasic encephalitis as the initial manifestation of AIDS.

J. Eron, R. Walters, Nathan D Lambert, 2006, Annals of internal medicine.

Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates

Cameron R. Wolfe, M. Hudgens, R. Baric, 2021, medRxiv.

Estimating a Set of Mortality Risk Functions with Multiple Contributing Causes of Death

Richard D Moore, S. Cole, M. Saag, 2020, Epidemiology.

Cervical cancer epidemiology among HIV-infected women in North America

Richard D Moore, J. Brooks, M. Gill, 2010, Infectious Agents and Cancer.

The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine.

R. Bosch, I. Frank, J. Eron, 2007, Journal of acquired immune deficiency syndromes.

Antiretroviral therapy: new drugs, formulations, ideas, and strategies.

J. Eron, 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Pre-treatment integrase strand transfer inhibitor resistance in north carolina from 2010-2016.

Ann M. Dennis, T. Menza, J. Eron, 2017, AIDS.

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART

A. Perelson, R. Koup, J. Casazza, 2018, Open forum infectious diseases.

Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016.

Ann M. Dennis, T. Menza, J. Eron, 2017, AIDS.

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens

J. Slim, J. Eron, M. Sulkowski, 2014, Journal of the International AIDS Society.

Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions.

J. Eron, 2008, The Journal of infectious diseases.

Vaporized Nicotine (E-Cigarette) and Tobacco Smoking Among People With HIV: Use Patterns and Associations With Depression and Panic Symptoms

K. Mayer, J. Eron, K. Cropsey, 2022, Journal of acquired immune deficiency syndromes.

Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy.

S. Cole, B. Lau, Jeffrey N. Martin, 2015, American journal of epidemiology.

Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095

Brent A. Johnson, J. Eron, R. Gulick, 2012, Journal of the American Statistical Association.

Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy

D. Margolis, S. Gianella, G. Jiang, 2023, The Journal of clinical investigation.

Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening.

Richard D Moore, J. Goedert, B. Lau, 2011, The Journal of infectious diseases.

HIV-1 Phylodynamics to Detect and Characterize Active Transmission Clusters in North Carolina.

Ann M. Dennis, W. Miller, J. Eron, 2019, The Journal of infectious diseases.

Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection

S. Deeks, J. Eron, M. Conant, 1996, The Lancet.

Development and integration of IPV-4, a patient-reported screening instrument of intimate partner violence for primary and HIV care

M. Mugavero, J. Eron, M. Kitahata, 2022 .

Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.

C. Hung, J. Slim, J. Eron, 2020, Journal of acquired immune deficiency syndromes.

Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19

E. Daar, C. Fletcher, C. Moser, 2023, JAMA network open.

Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020

Richard D Moore, M. Saag, Davey M. Smith, 2021, medRxiv : the preprint server for health sciences.

Comparing dynamic monitoring strategies based on evolving CD4 cell counts in virologically suppressed HIV-positive individuals on cART: a prospective observational study in high-income countries

Richard D Moore, C. Sabin, S. Boswell, 2017, The lancet. HIV.

Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting

J. Eron, D. Wohl, Claire E Farel, 2019, AIDS.

Use of Next Generation Sequencing in a State-Wide Strategy of HIV-1 Surveillance: Impact of the SARS-CoV-2 Pandemic on HIV-1 Diagnosis and Transmission.

Ann M. Dennis, Shuntai Zhou, R. Swanstrom, 2023, The Journal of infectious diseases.

Reply to Parikh and Mellors

J. Eron, C. Hurt, M. Cohen, 2012 .

Treatment Responses in Antiretroviral Treatment (ART) Naïve Pre-and Post-menopausal HIV-infected Women: An Analysis from ACTG Studies

S. Cohn, J. Eron, K. Patterson, 2009 .

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

E. Daar, C. Fletcher, C. Moser, 2023, Annals of Internal Medicine.

Clinical effectiveness of integrase strand transfer inhibitor-based antiretroviral regimens among adults with human immunodeficiency virus: a collaboration of cohort studies in the United States and Canada.

Jessie K. Edwards, Richard D Moore, S. Cole, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Fusion designs and estimators for treatment effects

Jessie K. Edwards, S. Cole, R. Brookmeyer, 2021, Statistics in medicine.

Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study.

Richard D Moore, Jennifer S. Lee, J. Margolick, 2019, The lancet. HIV.

Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors.

T. Kepler, M. Davidian, J. Frelinger, 1999, AIDS research and human retroviruses.

Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society–USA Panel

S. Hammer, R. Schooley, D. Richman, 2008 .

Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy.

L. Patton, J. Eron, R. Strauss, 2000, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity.

J. Frelinger, J. Eron, J. Eron, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

C. Orkin, J. Eron, J. Molina, 2019, AIDS Research and Therapy.

Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Identifying HIV care enrollees at-risk for cannabis use disorder

Richard D Moore, M. Mugavero, K. Mayer, 2017, AIDS care.

LB9. The Effect of Initiating Integrase Inhibitor-based vs. Non-Nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care

Richard D Moore, T. Sterling, M. Gill, 2019, Open Forum Infectious Diseases.

CD4 count at entry into HIV care and at antiretroviral therapy prescription in the US, 2005-2018.

Richard D Moore, Jennifer S. Lee, K. Buchacz, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018

Richard D Moore, Jennifer S. Lee, Jeffrey N. Martin, 2020, Clinical Infectious Diseases.

Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies.

S. Cohn, J. Eron, K. Patterson, 2009, Clinical Infectious Diseases.

Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19

A. Perelson, M. Hughes, W. Fischer, 2021, medRxiv.

Tobacco Smoking and Pack-Years Are Associated With Frailty Among People With HIV

S. Kritchevsky, S. Austad, P. Crane, 2023, Journal of Acquired Immune Deficiency Syndromes.

Prevention of HIV-1 infection with early antiretroviral therapy

S. Swindells, I. Hoffman, D. Celentano, 2011, Journal of Family Planning and Reproductive Health Care.

Second‐line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline *

J. Eron, M. Hosseinipour, J. Kumwenda, 2010, HIV medicine.

Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient.

W. Venter, J. Eron, I. Sanne, 2004, AIDS.

Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States

Richard D Moore, S. Cole, M. Brookhart, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers

E. Hyle, K. Freedberg, P. Sax, 2023, Open forum infectious diseases.

Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009.

Sally S Bebawy, Richard D Moore, J. Goedert, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients.

M. Hughes, B. Taiwo, S. Rosenkranz, 2013, AIDS research and human retroviruses.

Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study.

T. Sterling, J. Eron, S. Napravnik, 2013, AIDS research and human retroviruses.

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

D. Kuritzkes, E. Acosta, B. Taiwo, 2011, AIDS.

High clade C HIV-1 viremia: how did we get here and where are we going?

A. McMichael, K. Soderberg, J. Eron, 2011, AIDS.

End-stage renal disease among HIV-infected adults in North America.

Sally S Bebawy, K. Anastos, S. Gange, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody

A. Perelson, R. Ribeiro, E. Daar, 2023, bioRxiv.

Untreated HCV in HIV/HCV co-infection: Data from the TRIO network

P. Sax, J. Eron, D. Wyles, 2018 .

Second‐line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline *

J. Eron, M. Hosseinipour, J. Kumwenda, 2010, HIV medicine.

Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016

Jun Yu Li, S. Gange, J. Willig, 2023, PloS one.

Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

H. Stellbrink, R. Wood, F. Raffi, 2004, Antimicrobial Agents and Chemotherapy.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.

P. Volberding, H. Günthard, P. Sax, 2016, JAMA.

R5 Macrophage-Tropic HIV-1 in the Male Genital Tract

Shuntai Zhou, R. Swanstrom, I. Hoffman, 2015, Journal of Virology.

Generalizing evidence from randomized trials using inverse probability of sampling weights

Ashley L. Buchanan, S. Cole, M. Hudgens, 2018, Journal of the Royal Statistical Society. Series A,.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

D. Kuritzkes, P. Goulder, J. Ananworanich, 2019 .

The new england journal of medicine Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival

J. Goedert, B. Lau, R. Hogg, 2009 .

HIV post-treatment controllers have distinct immunological and virological features

R. Schooley, M. Lederman, D. Havlir, 2023, Proceedings of the National Academy of Sciences of the United States of America.

Prevalence and Comorbidity of Psychiatric Diagnoses Based on Reference Standard in an HIV+ Patient Population

W. Miller, B. Gaynes, J. Eron, 2008, Psychosomatic medicine.

Oral manifestations of HIV in a southeast USA population.

L. Patton, J. Eron, R. Strauss, 2008, Oral diseases.

Modeling Clinical Endpoints as a Function of Time of Switch to Second‐Line ART with Incomplete Data on Switching Times

Brent A. Johnson, J. Eron, R. Gulick, 2013, Biometrics.

Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine.

Jessie K. Edwards, M. Hudgens, A. Adimora, 2023, American journal of epidemiology.

Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry.

J. Eron, J. Hall, J. Eron, 2000, Journal of chromatography. B, Biomedical sciences and applications.

HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.

Ashley L. Buchanan, S. Cole, R. Haubrich, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.

J. Goedert, B. Lau, R. Hogg, 2011, American Journal of Epidemiology.

Decreasing Excess Mortality of HIV-Infected Patients Initiating Antiretroviral Therapy: Comparison with Mortality in General Population in China, 2003–2009

S. Cole, J. Eron, D. Wohl, 2013, Journal of acquired immune deficiency syndromes.

Immune Status and SARS-CoV-2 Viral Dynamics.

E. Daar, C. Moser, J. Currier, 2023, The Journal of infectious diseases.

Phylogenetic Evidence of HIV-1 Sequence Evolution in Subjects with Persistent Low-Level Viraemia

D. Kuritzkes, R. Bosch, B. Taiwo, 2015, Antiviral therapy.

Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts.

J. Willig, J. A. Delaney, P. Crane, 2014, American journal of epidemiology.

Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection

M. Lederman, A. Zolopa, P. Grant, 2010, PloS one.

Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort

Ann M. Dennis, A. Virkud, W. Miller, 2018, Open forum infectious diseases.

Variant-Specific Viral Kinetics in Acute COVID-19.

A. Perelson, R. Ribeiro, E. Daar, 2023, The Journal of infectious diseases.